Search results
Showing 91 to 105 of 267 results for obesity
The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.
Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1)
This guideline covers diagnosing and managing gastro-oesophageal reflux disease in children and young people (under 18s). It aims to raise awareness of symptoms that need investigating and treating, and to reassure parents and carers that regurgitation is common in infants under 1 year.
infection: What is the risk of early-onset neonatal infection with maternal obesity and how does this change with increasing body mass...
This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.
This guideline covers improving oral health by developing and implementing a strategy that meets the needs of people in the local community. It aims to promote and protect people’s oral health by improving their diet and oral hygiene, and by encouraging them to visit the dentist regularly.
Prevena incision management system for closed surgical incisions (MIB173)
NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .
NICE has developed a medtech innovation briefing (MIB) on the Somatom Definition Edge CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
Laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina (HTG464)
Evidence-based recommendations on laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina. This involves inserting mesh to hold the uterus or the top of the vagina in place.
View recommendations for HTG464Show all sections
This guideline covers the main risk factors linked with cardiovascular disease: poor diet, physical inactivity, smoking and excessive alcohol consumption. It aims to reduce the high incidence of cardiovascular disease. This, in turn, will help prevent other major causes of death and illness, such as type 2 diabetes and many cancers.
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.
Phentermine with topiramate for the treatment of obesity and overweight [ID543]
Discontinued Reference number: GID-TAG439
This quality standard covers identifying, assessing and managing chronic liver disease in children, young people and adults, and cirrhosis in young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS152Show all sections
Sections for QS152
- Quality statements
- Quality statement 1: Advice on physical activity, diet and alcohol
- Quality statement 2 (developmental): Testing for advanced liver fibrosis
- Quality statement 3 (developmental): Non-invasive testing for cirrhosis
- Quality statement 4: Surveillance for hepatocellular carcinoma
- Quality statement 5: Prophylactic intravenous antibiotics for upper gastrointestinal bleeding
- Update information
- About this quality standard
Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]
Discontinued Reference number: GID-TAG420